Loading
A phase 1/2 trial of Rondecabtagene autoleucel, Fludarabine, Cyclophosphamide in hodgkin lymphoma and non-hodgkin lymphoma, run by Lyell Immunopharma, Inc., now recruiting.
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma is a phase 1/2 interventional study registered as NCT05826535 by Lyell Immunopharma, Inc., with 270 participants planned, started 2023-05-09 and due to reach its primary completion in 2028-12-31. Interventions recorded: Rondecabtagene autoleucel (ronde-cel), Fludarabine, Cyclophosphamide. Conditions listed: Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Large B-cell Lymphoma. No results are recorded here; the registry entry is the source.
Shares Rondecabtagene autoleucel, Lyell Immunopharma, Hodgkin lymphoma.
Shares Fludarabine, Cyclophosphamide, Non-Hodgkin lymphoma (all types).
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.